Date: 2012-06-07
Type of information: Licensing agreement
Compound: Amorfix Aggregated Abeta Assay [the A4] (preclinical Alzheimer’s disease diagnostic test)
Company: Amorfix Life Sciences (Canada) JSW Lifesciences (Germany)
Therapeutic area: Neurodegenerative diseases
Type agreement: licensing
commercialisation
distribution
Action mechanism: The A4 is an ultra-sensitive assay that measures the levels of aggregated Abeta (beta amyloid) in brain, spinal fluid (CSF) and plasma from preclinical animal models used for Alzheimer’s disease research and drug development. The A4 enables the detection and quantitative measurement of aggregated Abeta, the building block of brain plaques and a hallmark of Alzheimer’s disease, up to a year earlier than conventional methods. As such, the A4 is a valuable tool to detect early Alzheimer’s changes in animal models, facilitating the development of therapeutics that can be used at earlier stages of the disease. The ability to detect and measure this direct biomarker of Alzheimer’s disease at such an early stage will also shorten discovery timelines and decrease costs at the preclinical phase of development.
Disease: Alzheimer's disease
Details: Amorfix Life Sciences Ltd has signed an agreement granting an exclusive worldwide license for its preclinical Alzheimer’s disease diagnostic test, the Amorfix Aggregated Abeta Assay (the A4) to JSW Lifesciences, a german contract research organization specializing in Alzheimer’s disease and other neurodegenerative disorders. Under the terms of the agreement, JSW will market and perform the A4 assay as a service in the area of preclinical Alzheimer’s disease studies. The agreement includes a commitment to minimum annual sales and Amorfix will receive a percentage of net sales. The Agreement was signed after the completion of due diligence on the technology by JSW, conducted pursuant to the Letter of Intent previously executed by the parties.
Financial terms:
Latest news:
